For the third patient (gastric cancer), the board suggested a combination of an immune checkpoint inhibitor with a multi-tyrosine-kinase inhibitor (off-label) because of hematologic toxicities from prior chemotherapy and the impossibility to include the patient in a clinical trial with a targeted agent for CLDN18.2 (Table 2). This evidence concerns the gene CLDN18 and gastric cancer.